Hyderabad: Booster The vaccine shot developed accidentally, after two doses can produce a strong antibody response and neutralized Omicron (B.
1.
529) and Delta (B.
1.
617.
2) SARS-COV-2 variants, a study What was done by Atlantabased Emory University has found.
In this study, it was carried out by the Emory Vaccine Center using the neutralization test of life viruses, 100% of serum test samples showed neutralization of Delta variants and more than 90% of serum samples showed neutralization of omicron variants, said Bharat Biotech on Wednesday.
As part of the study, which was determined to be published on the Preprint of MEDRXIV server immediately, blood serum was collected from 13 phase-2 covaxin clinical test participants (conducted by 2020) 28 days after they received their third shot (in 2021) analyzed for a response neutralize both variants.
All participants have received two first doses, 28 days apart and a third dose of six months after the second dose.
This study was sponsored by Bharat Biotech partners for US & Canada, Ocugen Inc.
The company has achieved its goal of making Vax global: Ellabharat Biotech said this study indicated that serum neutralization activity was enhanced by Covaxin proportional to what had been observed in the MRNA vaccine.
-Make serum against omicron variants, with more than 90% of all individuals driven by covaxin which shows neutralizing antibodies.
“These preliminary data shows that individuals who receive a dose of Covaxin booster have a significant immune response to the omicron and delta variants.
This finding shows that the booster dose has the potential to reduce the severity of the disease and hospitalization,” said Mehul Suthar, Assistant Professor of Emory Vaccine Center At Emory University, which leads laboratory analysis.
“The positive neutralization response to the omicron and delta variants, validating our hypothesis on multiepitop vaccines that produce immune response mediated humoral and cells,” said Chairman of Bharat Biotech & Managing Director Dr.
Krishna Ella, added that with Covaxin, the company has achieved it.
The aim of developing a global universal vaccine for adults and children.
According to Dr.
Shankar Musunuri, Chair, CEO & Co-Founder Ocugen Inc., this encouraging data shows the value of Covaxin as the main vaccine and booster.
“These results show how broad spectrum vaccines have potential capabilities to overcome the health challenges of the public who continue to shift like a new variant,” Dr Musunuri said.